Drug Trial Radar · NCT05089084
Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)
Last checked: Nov 19, 2026Latest source record: Jun 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
75
Actual
Start
Dec 14, 2021
Primary completion
Apr 29, 2024
Study completion Apr 21, 2026
Sponsor
- Lead sponsor
- Arrowhead PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Oct 22, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of AROAPOC3-3001 is to evaluate the efficacy and safety of ARO-APOC3 (plozasiran) in adult participants with familial chylomicronemia syndrome (FCS). Participants who have met all eligibility criteria will be randomized to receive 4 doses of plozasiran or matching placebo administered subcutaneously. Participants who complete the randomized period will continue in a 2-year open-label extension period where all participants will receive plozasiran.
Conditions
- Familial Chylomicronemia
Interventions
PlozasiranDrug
ARO-APOC3 subcutaneous (SC) injection
PlaceboDrug
sterile normal saline (0.9% NaCl) SC injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline at Month 10 in Fasting Triglycerides (TG)Time frame: Baseline, Month 10
Locations
58 sites in 21 countries. Site status is shown where the registry gives one.
Clinical Site 1
Boca Raton, Florida
Clinical Site 2
Suwanee, Georgia
Clinical Site 3
Indianapolis, Indiana
Clinical Site 4
Elkridge, Maryland
Clinical Site 5
St Louis, Missouri
Clinical Site 7
New York, New York
Clinical Site 6
New York, New York
Clinical Site 8
Austin, Texas
Clinical Site 9
Norfolk, Virginia
Clinical Site 10
Córdoba, Argentina
Clinical Site 11
Formosa, Argentina
Clinical Site 12
Melbourne, Australia
Clinical Site 13
Nedlands, Australia
Clinical Site 14
Camperdown, New South Wales, Australia
Clinical Site 15
St Leonards, New South Wales, Australia
Clinical Site 16
Melbourne, Victoria, Australia
Clinical Site 17
Graz, Austria
Clinical Site 18
Edegem, Belgium
Clinical Site 19
Ghent, Belgium
Clinical Site 20
Leuven, Belgium
Clinical Site 21
Liège, Belgium
Clinical Site 22
London, Ontario, Canada
Clinical Site 23
Toronto, Ontario, Canada
Clinical Site 24
Chicoutimi, Quebec, Canada
Clinical Site 25
Montreal, Quebec, Canada
Clinical Site 26
Québec, Quebec, Canada
Clinical Site 27
Zagreb, Croatia
Clinical Site 28
Paris, France
Clinical Site 29
Marseille, Cedez 05, France
Clinical Site 30
Jena, Germany
Clinical Site 31
Leipzig, Germany
Clinical Site 32
Galway, Ireland
Clinical Site 33
Jerusalem, Israel
Clinical Site 34
Chiba, Japan
Clinical Site 35
Ishikawa, Japan
Clinical Site 36
Osaka, Japan
Clinical Site 37
Tochigi, Japan
Clinical Site 38
Tokyo, Japan
Clinical Site 39
Tokyo, Japan
Clinical Site 40
Mexico City, Mexico
Showing 40 of 58 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.